The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache. And to assess the safety and tolerability of Timolol 0.5% ophthalmic solution in treatment of acute migraine headache.

Oral beta-blockers are a class of medications frequently used to control blood pressure, angina, and heart irregularities. Certain oral beta-blockers such as propranolol and timolol are used on a daily basis to prevent migraines. However, propranolol and timolol tablets have not been shown to be effective as an acute treatment to stop attacks of migraine because of their longer onset of action. We propose that, since beta-blocker eye drops, unlike tablets are quickly absorbed through the covering of the eye and lining of the nose and can be detected in the bloodstream within minutes, can be beneficial and efficacious in the treatment of headache abortion.

Timolol is a non-selective beta-adrenoreceptor antagonist. Oral timolol (20-30 mg daily) has been studied in 3 randomized controlled trials and have been found to reduce headache frequency by more than 50% when compared to placebo. It has been approved by FDA for prophylactic use in migraine patients and had level A evidence to support this indication. The prophylactic benefit of beta-blockers in migraine treatment is not completely understood. It may be related to the effect of beta-blockers on central autonomic vascular tone center, which in turn modulate the cerebrovascular reactivity to sensory stimulation.Propranolol, a beta-adrenergic blocker modulates serotonergic transmission, regulates peri aqueductal pathway activation and prevents central sensitization, normalizes neuronal excitability in the CNS, and blocks cortical spreading depression (CSD). Topical ocular beta blockers have been reported to be successful in retinal arteriolar spasm, retinal migraines causing visual field defects, migraines causing oculomotor nerve palsy, and as abortive agents in migraine patients. Topical timolol maleate solution 0.5% reaches a concentration of 0.5 ng/ml in the plasma within 4 hours of first dose after being used twice daily for 7 days.

Topical beta-blockers so far have been noted to be effective for acute migraine episodes only in case reports. We believe that this pilot study, to evaluate the efficacy and safety of a timolol eye drop for acute treatment of migraine headaches, will open doors for future trials and larger studies. If successful, this will be able establish the use of beta-blocker eye drops which is a simple, painless and low cost acute treatment of migraine.

The aim of this study is to determine the efficacy of timolol eye drops for the acute treatment of migraine.

Inclusion Criteria:

• Diagnosis of migraine, with or without aura, according to ICHD-2 criteria (Appendix A) for at least 1 year prior to screening; experience an average of 1 to 8 migraines per month.
• Females must be practicing an effective method of birth control before entry and throughout the study, or be surgically sterile, or be postmenopausal
• Females of child-bearing potential must have a negative urine pregnancy test
• Subjects should be able to demonstrate the ability to properly administer study medication
• Subjects should be able and willing to read and comprehend written instructions and complete the diary information required by the protocol
• Subjects must be capable, in the opinion of the Investigator, of providing informed consent or assent to participate in the study
• Subjects (and their legally acceptable representatives, if applicable) must provide an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

• Inability to distinguish other headaches from migraine
• Experiences headache of any kind at a frequency greater than or equal to 15 days per month
• Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening
• Chronic opioid therapy for headaches (> 3 consecutive days in the 30 days prior to screening)
• Hemiplegic migraine
• History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
• History of glaucoma and/or current treatment with prescription eye drops
• History of naso-lacrimal duct ("tear duct problem" to patients) obstruction or surgery for such
• Active treatment by ophthalmologist or optometrist for any severe ophthalmic disease or problem
• Any physical problems or co-ordination difficulty or eye avoidance sensitivity ("squeezer") that would preclude proper installation of eye drops in either or both eyes
• History of uncontrolled asthma, COPD, or reversible airway disease which in the opinion of the investigator would be worsened by the use of beta blockers
• History of clinically symptomatic bradycardia, congestive heart failure, or hypotension
• Uncontrolled Diabetes Mellitus
• Uncontrolled Hyperthyroidism
• History (within 2 years) of drug or alcohol abuse
• Systemic disease, which in the opinion of the Investigator, would contraindicate participation
• History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation
• History of hypersensitivity or intolerance to beta-blockers eye drops
• Pregnant or lactating women
• Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug
• Subjects, who in opinion of the Investigator, should not be enrolled in the study because of the precautions, warnings or contra-indications sections of the timolol Package Insert

Adverse event data was collected within 1 day of drug administration. All participants were advised to report any adverse event within 24 hours.

Participants were advised to call with minor side effects/ adverse events within 24 hours, and go to nearest ER in case of any serious adverse event.

Participant compliance was also found to be a big limitation with 6 participants considered as study drop outs since they did not return study drug/ forms even after repeated attempts to contact them. This led to loss of data.